Tirzepatide

Tirzepatide has been studied in 2,061 papers since 2018: 226 trials and 480 observational studies in people, 93 in animals, 24 in cells, 1,013 reviews; 904 in the past year. It is an approved medicine. The newest paper, Nov 17, 2026: “Painful Non‐Diabetic Lumbosacral Radiculoplexus Neuropathy Following Tirzepatide Exposure: A Case Report”.

InterventionGLP-1 receptor agonistsApproved 2022

2,061 papers study it23 more mention it2,399 findingsUpdated

PubChemMeSH

More peptides

236 new papers in 30 daysSee all 1,798 papers on tirzepatide

At a glance

Tirzepatide lowers cardiovascular and kidney event risk versus dulaglutide in a human trial; independent labs report lower weight and HbA1c in humans. An observational study links it with more atrial fibrillation and myocardial infarction than semaglutide in non-diabetic adults with obesity and established atherosclerotic cardiovascular disease. Eli Lilly funds papers and sponsors trials; human papers declare developer ties.

2,399 findings in 1,044 papers from 2020 to 2026, 260 of them since April 2026

Independent labs found the same change in mice and people. 435 independent labs in 55 countries; 181 trials, 73 about aging, 4 with no results posted.

“sotagliflozin (OR 0.50; 0.36-0.69; p-score=0.87), and tirzepatide (OR 0.55; 95% CI 0.33-0.92; p-score=0.80), had lowest odds of HF”
Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysisADA Scientific Sessions 2026 abstract2026doi:10.2337/db26-3089-lb

119 of its findings point the other way.

Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
  • 435 independent labs in 55 countries
  • 119 findings against
  • 181 trials, 73 about aging, 4 with no results posted
  • Funders: Eli Lilly and Company and others
  • 749 of 1,952 findings with company ties
  • 86 of 181 trials sponsored by its developers
  • Human trial217
  • Humans441
  • Animals33
  • Cells7
  • In silico52

218 studies gave tirzepatide to people and measured what changed.

What changedDesignPeopleSource

up: Increases gut microbiome alpha diversity

Randomized trial16 weeks36 peopleType 2 diabetesDiabetes, obesity & metabolism, Nov 8, 2026

down: Decreases predicted 10-year cardiovascular disease riskDifference versus placebo −2.4 percentage points (95% CI −3.4 to −1.4); estimated HR 0.77 (95% CI 0.69–0.85)

Randomized trial112 weeks, including 52 weeks of randomized maintenance133 peopleadultsObesity or overweight without diabetes or baseline cardiovascular disease; continued maximum tolerated dose versus switching to placebo after 60 weeks of tirzepatideAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases total first and recurrent MACE-5 eventsrate ratio 0.87 (95% CI 0.80–0.95); 1,489 versus 1,696 total events

Randomized trial13,165 peopleBothmean 64.1 yearsMidlife adults; type 2 diabetes and established atherosclerotic cardiovascular diseaseESC Congress 2026 abstract, Oct 26, 2026

up: Improves functional capacity

down: Decreases body weight

Trial24 weeks120 peopleBoth61±9 yearsMidlife adults; Older adults; HFpEF with or without type 2 diabetes; in addition to guideline-directed therapyESC Congress 2026 abstract, Oct 26, 2026

down: Decreases HbA1c-1.5%

up: Increases serum albumin

down: Decreases alanine transaminase

Treated cohort24 weeks88 peoplePatient cohortsEndocrine journal, Sep 29, 2026

What did studies of tirzepatide find?

289

Studies of tirzepatide measured 289 outcomes; the most studied are body weight (98 studies), HbA1c (37) and mortality (10).

Body weight

downin humans93downin mice3downin reviews2−17% mean weight loss, adherent patients

98 studies
  1. Tirzepatide decreases body weight in humans (HFpEF with or without type 2 diabetes; in addition to guideline-directed therapy).

    “preliminary analyses demonstrated significant reductions in body weight and improvement in metabolic parameters and functional capacity”

    Human trialHFpEF with or without type 2 diabetes; in addition to guideline-directed therapyup to 10 mg once weekly24 weeks64% womensn = 120

    Genomic profiling–guided evaluation of metabolic correction with tirzepatide in patients with HFpEF: results from a prospective controlled study in Kazakhstan

    ESC Congress 2026 abstract

  2. Tirzepatide decreases body weight in humans (single patient, dose escalation to 15 mg weekly) (<5% weight loss).

    “achieved minimal weight loss (<5%) despite tirzepatide dose escalation to 15 mg weekly over 6 months”

    Human trialsingle patient, dose escalation to 15 mg weekly15 mg weekly6 monthsmalesn = 1

    Tirzepatide non-response with subsequent semaglutide response in class 2 obesity

    JCEM case reports

  3. Tirzepatide decreases body weight in humans.

    “Participants treated with tirzepatide experienced greater reductions in BW and systolic blood pressure (SBP) compared with placebo, regardless of age subgroup, in each study.”

    Human trial52 weeks

    Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

  4. Tirzepatide decreases body weight in adults with early uncontrolled T2D.

    “tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”

    Human trialin adults with early uncontrolled T2D2 y

    In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y

    Annals of internal medicine

  5. Tirzepatide decreases body weight in humans (compared with placebo) (-19.28% (95% CI -20.39% to -18.16%) versus placebo).

    “followed by tirzepatide (-19.28%, -20.39% to -18.16%)”

    Human trialcompared with placebo

    Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials

    BMJ medicine

  6. Tirzepatide decreases body weight in humans (compared with semaglutide, after metabolic bariatric surgery) (mean difference 4.23% in favor of tirzepatide at 6 months).

    “At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide.”

    Human trialcompared with semaglutide, after metabolic bariatric surgery6 months

    Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis

    Frontiers in endocrinology

  7. Tirzepatide decreases body weight in humans (clinically meaningful (no value stated)).

    “Tirzepatide treatment was associated with clinically meaningful weight reduction”

    Human trial

    Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

    Diabetes, obesity & metabolism

  8. Tirzepatide decreases body weight in humans (-12.5 kg (-14%) from baseline).

    “Tirzepatide treatment resulted in a mean weight reduction of 12.5 kg (14%) of baseline weight”

    Human trial22 weeks

    Changes in Body Composition During and After Weight Loss with Tirzepatide

    ADA Scientific Sessions 2026 abstract

  9. Tirzepatide decreases body weight in humans (-14.6% (95% CI -15.5 to -13.8)).

    “Mean weight loss was −5.3% (95% CI −5.6 to −4.9) with liraglutide, −12.0% (−12.4 to −11.5) with semaglutide, and −14.6% (−15.5 to −13.8) with tirzepatide”

    Human trial15 mg once weekly

    Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2026 abstract

  10. Tirzepatide decreases body weight in humans (severe obstructive sleep apnea and morbid obesity) (-14 kg (-10.4%)).

    “The patient achieved a 14 kg weight reduction (10.4% total body weight loss).”

    Human trialsevere obstructive sleep apnea and morbid obesity2.5 mg weekly titrated to 5.0 mg weeklyapproximately 19 weeks and 4 daysmalesn = 1

    Disproportionate improvement in obstructive sleep apnea relative to weight loss following tirzepatide therapy

    Journal of Diabesity

All 100

HbA1c

downin humans37−1.5% to −0.6%

37 studies
  1. Tirzepatide decreases HbA1c in humans (unadjusted indirect comparison with semaglutide) (-0.10% vs semaglutide [-0.15, -0.05]).

    “HbA1c(-0.08% [-0.13,-0.03], -0.10% [-0.15, -0.05])”

    Human trialunadjusted indirect comparison with semaglutide15 mg/week

    Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

    International journal of obesity (2005)

  2. Tirzepatide decreases HbA1c in adults with early uncontrolled T2D.

    “tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”

    Human trialin adults with early uncontrolled T2D2 y

    In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y

    Annals of internal medicine

  3. Tirzepatide decreases HbA1c in a patient with severe hypertriglyceridemia and type 2 diabetes (to 5.5% from 7.0%).

    “HbA1c improved to 5.5%”

    Human trialin a patient with severe hypertriglyceridemia and type 2 diabetesfemalesn = 1

    Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report

    Cardiovascular diabetology. Endocrinology reports

  4. Tirzepatide decreases HbA1c in humans (compared with dulaglutide) (-2.18% (TZP) vs -1.28% (dula) at six months).

    “At six months HbA1c was reduced more with TZP than on dula (-2.18%, -1.28%, p<0.001)”

    Human trialcompared with dulaglutideup to 15 mg/weeksix monthsn = 449

    The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy

    ADA Scientific Sessions 2026 abstract

  5. Tirzepatide decreases HbA1c in humans (switch from dulaglutide, across prespecified baseline subgroups).

    “Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.”

    Human trialswitch from dulaglutide, across prespecified baseline subgroupsweek 40

    Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH

    BMJ open diabetes research & care

  6. Tirzepatide decreases HbA1c in humans (-0.77% (95% CI −0.98 to −0.56)).

    “At week 40, the estimated treatment difference of tirzepatide compared with dulaglutide was −0.77% (95% CI −0.98 to −0.56, p<0.001) for HbA1c and −6.9 kg (95% CI−8.3 to −5.5, p<0.001) for body weight.”

    Human trial40-week treatment periodn = 282

    Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH

    BMJ open diabetes research & care

  7. Tirzepatide decreases HbA1c in humans (tirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses) (MD 0.33%; 95% CI 0.20, 0.46).

    “tirzepatide was also more effective than semaglutide in reducing HbA1c (MD 0.33%; 95% CI: 0.20, 0.46)”

    Human trialtirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses15 mg versus 2.4 mg

    Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide

    Journal of diabetes

  8. Tirzepatide decreases HbA1c in humans (real-world pre-post treatment cohort).

    “The glucometabolic profile improved consistently, with declines in fasting glucose, insulin, HbA1c, and triglycerides, alongside higher HDL-c.”

    Human trialreal-world pre-post treatment cohort2.5 mg/week for 1 month, then 5.0 mg/weekmedian of 3 monthsn = 53

    Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss

    Frontiers in endocrinology

  9. Tirzepatide is linked with lower HbA1c in humans (-1.5%).

    “HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, -1.5%; BMI, -1.5 kg/m 2 ; both p < 0.001).”

    Humansaverage 4.5 ± 1.0 mg/week24 weeksn = 88

    Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study

    Endocrine journal

  10. Tirzepatide is linked with lower HbA1c in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (5.5 ± 0.4% to 5.2 ± 0.1%).

    “Metabolic parameters were also improved, including HbA1c (from 5.5 ± 0.4% to 5.2 ± 0.1%, p = 0.007)”

    Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122

    Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity

    Journal of diabetes and its complications

All 38

More on HbA1c

Mortality

downin humans6no changein humans4HR 0.6–0.99

10 studies
  1. Tirzepatide decreases mortality in humans (Type 2 diabetes and monovascular cardiovascular disease; compared with dulaglutide) (HR 0.86 (95% CI 0.75–0.99), p=0.03).

    “Risk of all-cause death was reduced on tirzepatide in both monovascular (HR=0.86 [0.75, 0.99], p=0.03) and polyvascular (HR=0.78 [0.64, 0.95], p=0.02) groups”

    Human trialType 2 diabetes and monovascular cardiovascular disease; compared with dulaglutiden = 10,309

    Major Cardiovascular Adverse Events in People with Type 2 Diabetes and Polyvascular Disease: Tirzepatide versus Dulaglutide

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide decreases mortality in humans (versus placebo in type 2 diabetes) (OR 0.72, 95% CI 0.64-0.82).

    “Tirzepatide (0.72, 0.64-0.82), SGLT2i (0.85, 0.80-0.91) and GLP1RA (0.85, 0.80-0.91) were associated with a significantly reduced mortality versus placebo”

    Human trialversus placebo in type 2 diabetesat least 40 weeks

    Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis

    Diabetes, obesity & metabolism

  3. Tirzepatide showed no clear effect on mortality in humans (odds ratio 1.02 (95% CI 0.57 to 1.81)).

    “Beta-binomial regression showed no evidence of a difference when assessing all-cause mortality (odds ratio 1.02, 95% CI 0.57 to 1.81; p = 0.95”

    Human trialplacebo-controlled trials in patients at increased risk of cardiovascular events; 21 trials

    The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

    BMC medicine

  4. Tirzepatide was not clearly linked with mortality in humans (Type 2 diabetes and heart failure with LVEF ≤50%; compared with GLP-1 receptor agonists) (4.3% vs 4.7%).

    “Mortality was similar (4.3% vs 4.7%; p=0.736)”

    HumansType 2 diabetes and heart failure with LVEF ≤50%; compared with GLP-1 receptor agonists365 days

    Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Heart Failure with Ejection Fraction 50% or Less: A Propensity Matched Analysis

    AHA Scientific Sessions 2026 abstract

  5. Tirzepatide was not clearly linked with mortality in humans (HR 0.99 [95% CI 0.81–1.21]; IR 20.5 vs. 19.5 per 1,000 person-years).

    “Rates of all-cause mortality between the exposure groups were similar”

    HumansAdults with heart failure with preserved ejection fraction and type 2 diabetes; compared with semaglutideOnce weeklyMedian follow-up of 5.1 months54% womensn = 37,183

    Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study

    Diabetes, obesity, and cardiometabolic CARE

  6. Tirzepatide was not clearly linked with mortality in humans (compared with semaglutide in a new-user active-comparator cohort).

    “No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.”

    Humanscompared with semaglutide in a new-user active-comparator cohort12 monthsn = 35,336

    Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults

    Diabetes, obesity & metabolism

  7. Tirzepatide is linked with lower mortality in humans (versus dulaglutide initiators) (HR 0.60, 95% CI 0.43-0.83).

    “which seemed to be driven by lower all-cause mortality among tirzepatide versus dulaglutide initiators (HR 0.60 [95% CI 0.43-0.83])”

    Humansversus dulaglutide initiators

    Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations

    Diabetes care

  8. Tirzepatide is linked with lower mortality in humans (obese patients with OSA treated with PAP) (RR:0.12; 95% CI:0.10-0.14, NNT=6).

    “lower mortality at 1 year (RR:0.14; 95% CI:0.12-0.17, NNT=9) and 3 years (RR:0.12; 95% CI:0.10-0.14, NNT=6).”

    Humansobese patients with OSA treated with PAP3 years

    Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP

    medRxivPreprint

  9. Tirzepatide decreases mortality in humans (type 2 diabetes; compared with dulaglutide; driven by the cardiovascular outcomes trial) (RR 0.85; CI 0.76 to 0.94).

    “All-cause mortality was lower with tirzepatide (RR 0.85; CI 0.76 to 0.94), driven by the cardiovascular outcomes trial.”

    Reviewtype 2 diabetes; compared with dulaglutide; driven by the cardiovascular outcomes trial

    Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety

    ESC Congress 2026 abstract

  10. Tirzepatide decreases mortality in humans (subgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists) (HR 0.85, 95% CI 0.76-0.94).

    “In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94)”

    Reviewsubgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists

    Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis

    Diabetes, obesity & metabolism

Body weight

downin humans8upin humans1

9 studies
  1. Tirzepatide decreases body weight in humans (unadjusted indirect comparison with semaglutide 2.4 mg/week) (-6.50 kg vs semaglutide [-8.03, -4.97]).

    “tirzepatide 10 and 15 mg demonstrated statistically significant improvements versus semaglutide in weight reduction (-5.10 kg [-6.63, - 3.57], -6.50 kg [-8.03,-4.97])”

    Human trialunadjusted indirect comparison with semaglutide 2.4 mg/week15 mg/week

    Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

    International journal of obesity (2005)

  2. Tirzepatide decreases body weight in humans (−6.50 kg [−8.03,−4.97]).

    “For efficacy estimand unadjusted ITCs, tirzepatide 10 and 15 mg demonstrated statistically significant improvements versus semaglutide in weight reduction (−5.10 kg [−6.63, − 3.57], −6.50 kg [−8.03,−4.97”

    Human trialWeek 72 SURMOUNT-1, Week 68 STEP 1

    Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

    International journal of obesity (2005)

  3. Tirzepatide decreases body weight in humans across baseline subgroups.

    “improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups”

    Human trialacross baseline subgroupsmaximum tolerated dose (10 mg or 15 mg)52 weeks

    Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

  4. Tirzepatide decreases body weight in humans (combined with low energy ketogenic therapy or low calorie diet).

    “Both groups achieved comparable reductions in BW after 12 weeks.”

    Human trialcombined with low energy ketogenic therapy or low calorie diet12 weeks

    Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis

    Nutrients

  5. Tirzepatide decreases body weight in humans (−10.2% ± 2.5 vs −9.8% ± 2.9).

    “As shown in, after 12 weeks of treatment, both groups exhibited significant reductions in body weight.”

    Human trial12 weeksn = 60

    Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis

    Nutrients

  6. Tirzepatide is linked with lower body weight in a patient with obesity and cardiometabolic comorbidities (-27.8% (126 kg to 91 kg)).

    “After 15 months of therapy, body weight decreased to 91 kg (-27.8%)”

    Humansin a patient with obesity and cardiometabolic comorbidities12.5 mg once weekly15 months

    Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities

    Meditsinskiy sovet = Medical Council

  7. Tirzepatide is linked with lower body weight in humans (median total body weight loss 12.6%).

    “At 12 months, median total body weight loss (TBWL) was 12.6%.”

    Humans12 months

    Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study

    Journal of the Endocrine Society

  8. Tirzepatide is linked with lower body weight in humans (patients with obesity) (-18.04 kg (-17.21%)).

    “At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline.”

    Humanspatients with obesitymedian 7.5 mg6 monthsn = 107

    Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study

    Clinical nutrition ESPEN

  9. Tirzepatide is linked with lower body weight in type 1 diabetes and obesity (13.4 kg [11.0, 15.8]).

    “weight (13.4 kg [11.0, 15.8], p < 0.001) and total daily insulin dose (29.9 units [16.9, 42.9], p < 0.001).”

    Humansin type 1 diabetes and obesity5 mg weekly12 months

    Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

    Diabetes, obesity & metabolism

  10. Tirzepatide is linked with lower body weight in humans (combined with lifestyle modification) (-3.73±2.44 kg after 12 weekly doses).

    “with BMI (kg/m2), weight (kg), WC (cm), FBS (mg/dL), and PPBS (mg/dL) decreasing by 1.16±0.90, 3.73±2.44, 2.19±0.27, 22.34±24.69, and 52.63±48.02 after 12 weekly doses”

    Humanscombined with lifestyle modification12 weekly dosesn = 21

    Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity

    ADA Scientific Sessions 2026 abstract

All 11

More on Body weight

Apnea-hypopnea index

downin humans5downin reviews1

6 studies
  1. Tirzepatide decreases apnea-hypopnea index in humans (compared with placebo, across baseline subgroups) (-27.7 to -34.1 events/h by baseline age subgroup).

    “Participants treated with tirzepatide experienced reductions in AHI across subgroups, regardless of baseline age (-27.7 to -34.1 events/h), sex (-19.8 to -32.6 events/h)”

    Human trialcompared with placebo, across baseline subgroupsmaximum tolerated dose (10 mg or 15 mg)52 weeks

    Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

  2. Tirzepatide decreases apnea-hypopnea index in humans.

    “In both studies, tirzepatide treatment was associated with a greater reduction in AHI and SASHB than placebo, regardless of baseline age.”

    Human trial52 weeks

    Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

  3. Tirzepatide decreases apnea-hypopnea index in humans (MD -21.85 events/h, 95% CI [-27.52, -16.34]).

    “The NMA results suggested that tirzepatide ranking highest of producing the greatest AHI reduction (MD = -21.85 events/h, 95 % CI [-27.52, -16.34])”

    Human trial

    Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis

    Respiratory medicine

  4. Tirzepatide decreases apnea-hypopnea index in humans (obstructive sleep apnea with concurrent obesity).

    “tirzepatide produced randomized, placebo-controlled reductions in the apnea-hypopnea index, sleep apnea-specific hypoxic burden, body weight, and systemic inflammation.”

    Reviewobstructive sleep apnea with concurrent obesity

    Tirzepatide for the treatment of obstructive sleep apnea: from apnea-hypopnea index reduction to cardiometabolic risk mitigation–a narrative review

    Multidisciplinary respiratory medicine

  5. Tirzepatide decreases apnea-hypopnea index in humans (obstructive sleep apnea; compared with placebo) (MD −21.96 events/h; 95% CI, −26.16 to −17.76).

    “tirzepatide (MD −21.96 events/h; 95% CI, −26.16 to −17.76) demonstrated the highest efficacy in AHI reduction.”

    Reviewobstructive sleep apnea; compared with placebo

    Comparative Efficacy of Weight-Loss and Diuretic-Based Pharmacotherapies for Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis

    Frontiers in neurology

  6. Tirzepatide decreases apnea-hypopnea index (obesity-related OSA).

    “Incretin-based therapies, particularly tirzepatide, have emerged as promising treatments for obesity-related OSA following the SURMOUNT-OSA trial, demonstrating significant reductions in apnea–hypopnea index”

    Reviewobesity-related OSA

    Management of Obstructive Sleep Apnea in People with Type 2 Diabetes

    Diabetology

  7. Tirzepatide decreases apnea-hypopnea index in humans (moderate to severe obstructive sleep apnea and obesity).

    “In patients with moderate to severe OSA and obesity, tirzepatide reduced the apneahypopnea index”

    Reviewmoderate to severe obstructive sleep apnea and obesity

    Tirzepatide – alternative to CPAP-therapy or new opportunity in the therapy of obstructive sleep apnea?

    Meditsinskiy sovet = Medical Council

C-reactive protein

downin humans6

6 studies
  1. Tirzepatide decreases C-reactive protein in humans (vs placebo plus lifestyle modification) (-55.1% and -65.3% vs -17.7%).

    “reduced leptin (-57.3% and -63.1% vs -8.4%), high-sensitivity C-reactive protein (-55.1% and -65.3% vs -17.7%)”

    Human trialvs placebo plus lifestyle modification10 or 15 mg72 weeks

    Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  2. Tirzepatide decreases C-reactive protein in obese patients undergoing transfemoral TAVR (marked reduction, not quantified).

    “Tirzepatide was associated with marked reductions in CRP and body weight”

    Human trialin obese patients undergoing transfemoral TAVR

    Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial

    Cardiovascular revascularization medicine : including molecular interventions

  3. Tirzepatide is linked with lower C-reactive protein in humans (concurrent with biologic therapy in obese psoriatic arthritis) (4.2±3.8 vs 7.7±3.0 mg/L).

    “and lower CRP (4.2±3.8 vs 7.7±3.0 mg/L, p<0.001).”

    Humansconcurrent with biologic therapy in obese psoriatic arthritis2.5 mg/week uptitrated to 5 mg/week6 months

    Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study

    RMD open

  4. Tirzepatide is linked with lower C-reactive protein in Indian patients with obesity (declined 30-43%).

    “hs-CRP declined 30-43% (p<0.0001).”

    Humansin Indian patients with obesity24 weeksn = 91

    Tirzepatide Induced Cardiometabolic Transformation in Indian Patients with Obesity: A Prospective Cohort Study

    ADA Scientific Sessions 2026 abstract

  5. Tirzepatide decreases C-reactive protein in humans (29–55% reduction).

    “lowers high-sensitivity C-reactive protein (hsCRP) by 29–55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea”

    ReviewTrials in obesity, heart failure with preserved ejection fraction, and obstructive sleep apnea

    Tirzepatide and inflammation: a critical reappraisal of the immunometabolic case for incretin-based therapy

    Reviews in endocrine & metabolic disorders

  6. Tirzepatide decreases C-reactive protein in humans (Compared with placebo or standard of care; six studies) (-34.3% (95% CI -38.4% to -30.1%)).

    “Tirzepatide significantly reduced hsCRP by 34.3% (95% CI: -38.4% to -30.1%; P < .0001; I2 = 0.0%; 6 studies)”

    ReviewCompared with placebo or standard of care; six studies

    Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis

    The Journal of clinical endocrinology and metabolism

More on C-reactive protein

Lean mass

downin humans4downin reviews1−11% lean mass

5 studies
  1. Tirzepatide decreases lean mass in humans (overweight or obesity).

    “The publications examined indicated that treatment with semaglutide and tirzepatide may promote reductions in both fat mass and lean mass.”

    Reviewoverweight or obesity

    Preservation of muscle mass during pharmacological treatment of obesity: evidence on nutritional strategies and physical exercise in users of GLP-1 agonists and dual GIP/GLP-1 agonists — a systematic review

    Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida

  2. Tirzepatide decreases lean mass in humans (SURMOUNT-1 body composition substudy) (10.9% reduction in lean mass).

    “participants treated with tirzepatide showed mean reductions of 21.3% in body weight, 33.9% in fat mass and 10.9% in lean mass over 72 weeks”

    ReviewSURMOUNT-1 body composition substudy72 weeks

    Tirzepatide, body composition and risk of sarcopenia: a critical narrative review

    LUMEN ET VIRTUS

  3. Tirzepatide decreases lean mass in humans (obesity; SURMOUNT-1 substudy) (10.9% reduction in lean mass).

    “tirzepatide promoted reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass over 72 weeks.”

    Reviewobesity; SURMOUNT-1 substudy72 weeks

    SARCOPENIA DURING PHARMACOLOGICAL TREATMENT OF OBESITY: ASSESSMENT OF BODY COMPOSITION AND STRATEGIES FOR MUSCLE PRESERVATION

    Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida

  4. Tirzepatide decreases lean mass.

    “although a reduction in lean mass may also occur.”

    Review

    Tirzepatide and the quality of weight loss: preservation of lean mass, body composition, and risk of frailty

    Aposta

  5. Tirzepatide decreases lean mass in humans.

    “A similar trend has been described in patients treated with tirzepatide.”

    Review

    Preserving Lean Mass During GLP-1RA-Induced Weight Loss: The Potential Role of Ketogenic Metabolic Therapy in Improving Weight-Loss Quality

    Biomedicine Advances

Gastrointestinal adverse events

no changein humans3upin humans2+59%

5 studies
  1. Tirzepatide increases gastrointestinal adverse events in humans (compared with dulaglutide) (2827 patients (42.5%) vs 2387 patients (35.9%)).

    “Gastrointestinal adverse events were more common with tirzepatide (2827 patients [42.5%]) than dulaglutide (2387 patients [35.9%]) treatment.”

    Human trialcompared with dulaglutideup to 15 mg weeklymedian 46.9 monthsn = 13,165

    Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial

    JAMA cardiology

  2. Tirzepatide was not clearly linked with gastrointestinal adverse events in humans (landmark target trial emulation).

    “Rates of expected gastrointestinal adverse events were comparable between groups.”

    Humanslandmark target trial emulation2 yearsn = 1,594

    Early tirzepatide after kidney transplantation in diabetes is associated with lower cardiovascular events and graft failure: a multinational target trial emulation

    ESC Congress 2026 abstract

  3. Tirzepatide is linked with higher gastrointestinal adverse events in humans (real-world retrospective cohort, 3-month follow-up) (59.2%).

    “Gastrointestinal adverse events were common (59.2%) but predominantly mild to moderate.”

    Humansreal-world retrospective cohort, 3-month follow-up3 monthsn = 71

    Early Metabolic and Hepatic Benefits of Tirzepatide in Indian Adults with Type 2 Diabetes: Insights from Real-World Practice

    ADA Scientific Sessions 2026 abstract

  4. Tirzepatide was not clearly linked with gastrointestinal adverse events in humans (compared with semaglutide).

    “Gastrointestinal AEs did not differ between the two groups.”

    Humanscompared with semaglutide

    Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes

    Diabetes technology & therapeutics

  5. Tirzepatide showed no clear effect on gastrointestinal adverse events in humans (versus semaglutide) (risk ratio 1.08, 95% CI 0.97-1.20).

    “Rates of gastrointestinal adverse events were comparable between groups (risk ratio 1.08, 95% CI 0.97-1.20)”

    Reviewversus semaglutide

    Dual Incretin Therapy vs. GLP-1 Monotherapy: Meta-Analysis of Tirzepatide and Semaglutide in Adults with Type 2 Diabetes

    ADA Scientific Sessions 2026 abstract

Fat mass

downin humans3downin reviews2−34% fat mass

5 studies
  1. Tirzepatide is linked with lower fat mass in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (-35%).

    “Fat mass (FM) largely reduced by 35%, fat-free mass slightly decreased by 5% (p < 0.001 for both)”

    Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122

    Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity

    Journal of diabetes and its complications

  2. Tirzepatide decreases fat mass in humans (SURMOUNT-1 body composition substudy) (33.9% reduction in fat mass).

    “participants treated with tirzepatide showed mean reductions of 21.3% in body weight, 33.9% in fat mass and 10.9% in lean mass over 72 weeks”

    ReviewSURMOUNT-1 body composition substudy72 weeks

    Tirzepatide, body composition and risk of sarcopenia: a critical narrative review

    LUMEN ET VIRTUS

  3. Tirzepatide decreases fat mass.

    “most of the weight loss associated with tirzepatide corresponds to a reduction in fat mass, including visceral and ectopic fat”

    Review

    Tirzepatide and the quality of weight loss: preservation of lean mass, body composition, and risk of frailty

    Aposta

  4. Tirzepatide decreases fat mass (obesity treatment).

    “Semaglutide and tirzepatide preferentially reduce fat mass, including visceral and ectopic adiposity, while producing smaller but consistent reductions in lean mass or lean soft tissue.”

    Reviewobesity treatment

    Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies

    Metabolites

  5. Tirzepatide decreases fat mass in individuals with overweight and obesity.

    “mainly through a reduction in fat mass.”

    Reviewin individuals with overweight and obesity

    Effects of tirzepatide on weight loss and body composition: clinical and functional implications

    Revista Ibero-Americana de Humanidades, Ciências e Educação

Triglyceride

downin humans4

4 studies
  1. Tirzepatide decreases triglyceride in a patient with severe hypertriglyceridemia and type 2 diabetes (from 335 mg/dL to 85 mg/dL at 12 months).

    “triglycerides normalized to 137 mg/dL at 3 months and 85 mg/dL at 12 months”

    Human trialin a patient with severe hypertriglyceridemia and type 2 diabetes12 monthsfemalesn = 1

    Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report

    Cardiovascular diabetology. Endocrinology reports

  2. Tirzepatide decreases triglyceride in humans (versus liraglutide).

    “All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide”

    Human trialversus liraglutide5, 10 and 15 mg

    Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials

    Advances in therapy

  3. Tirzepatide is linked with lower triglyceride in humans (real-world retrospective cohort, 3-month follow-up) (−46.4 mg/dL).

    “Significant improvements were observed in systolic blood pressure (−5.6 mmHg), triglycerides (−46.4 mg/dL)”

    Humansreal-world retrospective cohort, 3-month follow-up3 monthsn = 71

    Early Metabolic and Hepatic Benefits of Tirzepatide in Indian Adults with Type 2 Diabetes: Insights from Real-World Practice

    ADA Scientific Sessions 2026 abstract

  4. Tirzepatide is linked with lower triglyceride in humans (compared with liraglutide and semaglutide groups) (greater reduction than in the other groups).

    “Improvements in lipid parameters were observed across all groups, with greater triglyceride reduction in the tirzepatide group.”

    Humanscompared with liraglutide and semaglutide groups36 weeks

    Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study

    Diabetes, metabolic syndrome and obesity : targets and therapy

More on Triglyceride

6-minute walk distance

upin humans3

3 studies
  1. Tirzepatide improves 6-minute walk distance in humans (at 52 weeks) (+18 (95% CI 5, 31) m for women vs +15 (95% CI −2, 31) m for men).

    “There were no differences by sex in the effect of tirzepatide on 6MWD at 52 weeks (+18 (95% CI 5, 31) m for women vs +15 (95% CI −2, 31) m for men, interaction p=0.761).”

    Human trialat 52 weeks5 mg to 15 mg/weekn = 731

    Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial

    JACC. Heart failure

  2. Tirzepatide is linked with better 6-minute walk distance in humans (obesity-related HFpEF, prospective real-world cohort) (+43 m).

    “6-min walk distance by +43 m (q < 0.001)”

    Humansobesity-related HFpEF, prospective real-world cohortmedian follow-up 5.8 monthsn = 50

    Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study

    International journal of cardiology

  3. Tirzepatide improves 6-minute walk distance in humans (SUMMIT trial) (+15.8 m).

    “In the SUMMIT trial, KCCQ-CSS improved by 5.1 points (P < .001) and 6 MWT by 15.8 m (P = .004).”

    ReviewSUMMIT trial

    Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis

    The Journal of clinical endocrinology and metabolism

Cardiometabolic risk factors

downin humans2upin humans1

3 studies
  1. Tirzepatide decreases cardiometabolic risk factors in humans.

    “favourable treatment differences in cardiometabolic risk factors and quality-of-life measures in adults ≥ 65 years”

    Human trial

    Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials

    Diabetes, obesity & metabolism

  2. Tirzepatide decreases cardiometabolic risk factors in humans (obstructive sleep apnea and obesity; compared with placebo).

    “tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo.”

    Human trialobstructive sleep apnea and obesity; compared with placebo52 weeks

    Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

    Nature medicine

  3. Tirzepatide improves cardiometabolic risk factors in humans.

    “Tirzepatide also improved cardiometabolic risk factors, body composition, physical functioning, and health-related quality of life.”

    Review

    Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review

    Cureus

Body mass index

downin humans3

3 studies
  1. Tirzepatide decreases body mass index in participants who shifted to a lower BMI category (-8.90 vs -3.65 kg/m2 (SURMOUNT-1); -10.47 vs -5.20 kg/m2 (SURMOUNT-4)).

    “Among these participants, mean BMI reductions were greater than in those without improvement (SURMOUNT-1: -8.90 vs -3.65 kg/m2; SURMOUNT-4: -10.47 vs -5.20 kg/m2).”

    Human trialin participants who shifted to a lower BMI category72 weeks (SURMOUNT-1); 88 weeks (SURMOUNT-4)

    Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials

    American journal of preventive cardiology

  2. Tirzepatide is linked with lower body mass index in humans (concurrent with biologic therapy in obese psoriatic arthritis) (-2.9±2.0 vs +0.4±1.2 kg/m2).

    “The tirzepatide group showed greater BMI reduction (-2.9±2.0 vs +0.4±1.2 kg/m2, p<0.001)”

    Humansconcurrent with biologic therapy in obese psoriatic arthritis2.5 mg/week uptitrated to 5 mg/week6 months

    Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study

    RMD open

  3. Tirzepatide decreases body mass index in humans (-1.2 kg/m2 absolute reduction (95% CI -5.9 to -1.1)).

    “body mass index of -1.2 kg/m2 (95% CI: -5.9 to -1.1)”

    Reviewpooled across four non-randomized observational studies in solid organ transplant recipients

    Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis

    Frontiers in pharmacology

More on Body mass index

Serious adverse events

no changein humans2

2 studies
  1. Tirzepatide showed no clear effect on serious adverse events in humans (odds ratio 0.98 (95% CI 0.82 to 1.17)).

    “or SAEs (odds ratio 0.98, 95% CI 0.82 to 1.17; p = 0.80; 21 trials”

    Human trialplacebo-controlled trials in patients at increased risk of cardiovascular events; 21 trials

    The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

    BMC medicine

  2. Tirzepatide showed no clear effect on serious adverse events in humans (Overweight or obesity; versus placebo).

    “The risks of developing any serious AEs with the use of tirzepatide, semaglutide, orlistat, and sibutramine were not statistically different from those with placebo.”

    ReviewOverweight or obesity; versus placebo

    Safety evaluation of medications for the treatment of obesity or excessive body weight: a systematic review and data meta-analysis

    Terapevticheskii arkhiv

Predicted 10-year cardiovascular disease risk

downin humans2HR 0.77

2 studies
  1. Tirzepatide decreases predicted 10-year cardiovascular disease risk in humans (Difference versus placebo −2.4 percentage points (95% CI −3.4 to −1.4); estimated HR 0.77 (95% CI 0.69–0.85)).

    “After 112 weeks, TZP MTD was associated with a significant reduction in predicted 10-year CVD risk when compared to switching to placebo”

    Human trialObesity or overweight without diabetes or baseline cardiovascular disease; continued maximum tolerated dose versus switching to placebo after 60 weeks of tirzepatide10 mg or 15 mg once weekly112 weeks, including 52 weeks of randomized maintenancen = 133

    Trajectory of Predicted 10-year Cardiovascular Disease Risk with Tirzepatide Dose Modifications: A Post-Hoc Analysis from the SURMOUNT-MAINTAIN Trial

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide decreases predicted 10-year cardiovascular disease risk in humans (people with obesity/overweight and prediabetes, SURMOUNT-1 post hoc analysis) (ARR -1.92% at week 72).

    “receiving tirzepatide 15 mg was associated with a reduction in the predicted 10-year CVD risk at week 72 (absolute risk reduction, (ARR) -1.92%)”

    Human trialpeople with obesity/overweight and prediabetes, SURMOUNT-1 post hoc analysis15 mg72 weeksn = 962

    Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity

    European journal of preventive cardiology

More on Predicted 10-year cardiovascular disease risk

All 289

What is tirzepatide linked with?

196

Studies link tirzepatide with 196 measures, among them body weight, mortality and major adverse cardiovascular events.

Body weight

downin humans18downin reviews1

19 studies
  1. Tirzepatide is associated with body weight in humans (Normoglycemic individual treated for weight loss).

    “Tirzepatide exposure was associated with rapid weight loss in a normoglycaemic individual.”

    HumansNormoglycemic individual treated for weight lossmalesn = 1

    Painful Non‐Diabetic Lumbosacral Radiculoplexus Neuropathy Following Tirzepatide Exposure: A Case Report

    Journal of the peripheral nervous system : JPNS

  2. Tirzepatide is associated with body weight in humans (60.7% reported >10% weight reduction).

    “60.7% had achieved >10% reduction”

    HumansParticipants with psoriasis and obesity/overweight taking concomitant ixekizumab and tirzepatide; self-reported change since starting tirzepatide82.0% femalesn = 89

    Real-World Patient Experiences With Concomitant Ixekizumab and Tirzepatide in Psoriasis: Participants Recruited From the Zepbound® Savings for Taltz® US Customer Support Program

    Skin (Milwood, N.Y.)

  3. Tirzepatide is associated with body weight in humans (obesity) (Median weight loss 8.3% at 3 months and 15.0% at 6 months).

    “Median weight loss was 8.3% and 15.0% at 3 and 6 months, respectively.”

    Humansobesity6 monthsn = 76

    Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity

    Obesity research & clinical practice

  4. Tirzepatide is associated with body weight in humans (Obesity without diabetes) (30.4% achieved ≥5% total body weight loss; 22.5% achieved ≥10%).

    “corresponding rates were 30.4% and 22.5% among tirzepatide initiators.”

    HumansObesity without diabetesInjectable12 monthsn = 296,817

    The Real-World GLP-1 Care Pathway for Obesity Treatment: Persistence, Dose Attainment, Monitoring, and Weight Loss Response

    AHA Scientific Sessions 2026 abstract

  5. Tirzepatide is associated with body weight in humans (Switching from semaglutide to tirzepatide versus continuing semaglutide) (3.0 kg greater weight reduction (95% CI, 1.2–5.0)).

    “switching to tirzepatide produced greater weight reduction than continuing semaglutide (difference of 3.0 kg, 95% CI, 1.2–5.0)”

    HumansSwitching from semaglutide to tirzepatide versus continuing semaglutide2 years after target trial emulation enrollmentn = 15,154

    Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide: a target trial emulation using data from Cleveland Clinic electronic health records

    EClinicalMedicine

  6. Tirzepatide is associated with body weight in humans (Body weight −11.22 kg (10.4%); fat mass −7.90 kg (16.8%); BIA-derived fat-free mass −3.35 kg (5.4%)).

    “Estimated marginal body weight fell by 11.22 kg (10.4%), fat mass by 7.90 kg (16.8%), and BIA-derived FFM by 3.35 kg (5.4%) at 12 weeks”

    Humansadults with obesity receiving tirzepatide monotherapy; available-data, on-treatment estimates12 weeks66% females

    Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study

    Journal of clinical medicine

  7. Tirzepatide is associated with body weight in humans (Compared with dulaglutide in breast cancer patients receiving concurrent endocrine therapy) (-4.7% versus +0.1% with dulaglutide; overall agent comparison p = 0.003).

    “semaglutide (- 5.8%) and tirzepatide (- 4.7%) outperformed dulaglutide (+ 0.1%)”

    HumansCompared with dulaglutide in breast cancer patients receiving concurrent endocrine therapyOne year

    GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis

    Breast cancer research and treatment

  8. Tirzepatide is associated with body weight in humans (obesity; unsupervised use) (15 kg weight loss).

    “self-administered tirzepatide, lost 15 kg over about 3 months”

    Humansobesity; unsupervised useabout 3 monthsmalesn = 1

    Case Report: GADA-positive type 1 diabetes with diabetic ketoacidosis in a young adult with obesity temporally associated with unsupervised tirzepatide use for weight reduction

    Frontiers in endocrinology

  9. Tirzepatide is associated with body weight in humans (Obesity) (11 kg in the man and 9 kg in the woman).

    “At 3 months, body weight had decreased by 11 kg and 9 kg, respectively.”

    HumansObesityStarting at 2.5 mg once weekly for 4 weeks, titrated up to 10 mg weekly3 monthsBothsn = 2

    Reduction of Cocaine Craving and Sustained Abstinence During Tirzepatide Treatment in Two Patients with Obesity: A Case Report

    Preprints.orgPreprint

  10. Tirzepatide is associated with body weight in humans (Chronic kidney disease stages 1–5, type 2 diabetes mellitus and obesity) (Median weight 103 to 100 kg; p < 0.0001).

    “Tirzepatide significantly reduced median weight (103-100 kg; p < 0.0001), HbA1c (63 [7.9%] to 54 [7.1%] mmol/mol; p = 0.002)”

    HumansChronic kidney disease stages 1–5, type 2 diabetes mellitus and obesityMedian 21.4 weeksn = 62

    Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

    Diabetic medicine : a journal of the British Diabetic Association

All 19

Mortality

downin humans19HR 0.1–0.8

19 studies
  1. Tirzepatide is associated with mortality in humans (3-year HR 0.67 (95% CI 0.46–0.98)).

    “All-cause mortality was lower with TZP at 3years (HR 0.67, 0.46-0.98, p=0.04).”

    HumansNon-diabetic adults with obesity and established atherosclerotic cardiovascular disease; compared with semaglutide3 years

    Tirzepatide linked to more atrial fibrillation than semaglutide

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide is associated with mortality in humans (Type 2 diabetes; compared with metformin) (1-year HR 0.344; RR 0.302; all p<0.0001).

    “tirzepatide (1-year: RR 0.302, HR 0.344; extended [364 vs 730 days]: RR 0.220, HR 0.466; all p<0.0001)”

    HumansType 2 diabetes; compared with metformin1 year

    Diabetes drugs linked to fewer deaths in young adults

    AHA Scientific Sessions 2026 abstract

  3. Tirzepatide is associated with mortality in humans (PCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide) (0.2% vs 1.5%; HR 0.10, 95% CI 0.02–0.40).

    “Tirzepatide use was associated with lower five-year hazards of all-cause mortality (0.2% vs 1.5%; HR, 0.10; 95% CI, 0.02 - 0.40; p<0.01)”

    HumansPCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide5 yearsfemalesn = 4,345

    Five-Year Cardiovascular Outcomes of Tirzepatide in Women with Polycystic Ovarian Syndrome and Type 2 Diabetes Mellitus Receiving Metformin

    AHA Scientific Sessions 2026 abstract

  4. Tirzepatide is associated with mortality in humans (Adults with serious mental illness; compared with SGLT2 inhibitors) (RR 0.27; P<.0001).

    “Mortality reductions were driven by semaglutide (RR 0.55) and tirzepatide (RR 0.27; P<.0001)”

    HumansAdults with serious mental illness; compared with SGLT2 inhibitors

    Diabetes drugs linked to fewer deaths in serious mental illness

    AHA Scientific Sessions 2026 abstract

  5. Tirzepatide is linked with a lower risk of mortality in humans (HR 0.38 (95% CI 0.25–0.58)).

    “all-cause mortality (HR, 0.38; 95% CI, 0.25–0.58)”

    Humansin adults with obesity and major depressive disorder, compared with non-GLP-1RA anti-obesity medicationsn = 24,103

    Association between tirzepatide use and risk of suicidal ideation among individuals with obesity and major depressive disorder

    Translational psychiatry

  6. Tirzepatide is associated with mortality in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide) (1-year HR 0.75; 3-year HR 0.78).

    “tirzepatide was associated with lower cardiovascular and renal event rates than semaglutide, with comparable safety.”

    HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide3 years

    Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study

    Clinical Medicine Insights. Cardiology

  7. Tirzepatide is associated with mortality in humans (HR 0.55, 95% CI 0.42–0.72).

    “Outcomes were similar between TZP and GLP-1RA, except TZP showed lower mortality (HR 0.55 [95% CI 0.42-0.72]).”

    HumansCoexisting COPD and type 2 diabetes; compared with other glucagon-like peptide-1 receptor agonistsDay 1 through day 365n = 6,727

    Tirzepatide linked to fewer chronic lung disease flare-ups

    Frontiers in pharmacology

  8. Tirzepatide is associated with mortality in humans (Patients with type 2 diabetes; compared with semaglutide) (0.6% vs. 0.9%; ARD -0.3% (95% CI -0.33 to -0.24); HR 0.8 (95% CI 0.74–0.84)).

    “all-cause mortality (0.6% vs. 0.9%; ARD - 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84)”

    HumansPatients with type 2 diabetes; compared with semaglutide

    Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes

    Journal of diabetes and metabolic disorders

  9. Tirzepatide is linked with a lower risk of mortality in humans (compared with semaglutide in patients with obesity) (HR 0.8).

    “The tirzepatide group were also at lower risk of all-cause mortality (HR, 95% CI: 0.8, 0.77─0.91)”

    Humanscompared with semaglutide in patients with obesityone yearn = 424,269

    New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide

    medRxivPreprint

  10. Tirzepatide is linked with a lower risk of mortality in humans (versus GLP-1 receptor agonists) (HR 0.69, 95% CI 0.59-0.80).

    “Tirzepatide was associated with lower risks of mortality (HR 0.69, 95% CI 0.59-0.80), periodontitis (0.70, 0.57-0.86), tooth extraction (0.89, 0.84-0.94), peri-implant complications (0.61, 0.52-0.70)”

    Humansversus GLP-1 receptor agonists1-year follow-upn = 97,993

    Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study

    Diabetes research and clinical practice

All 19

Major adverse cardiovascular events

downin humans10RR 0.339–0.56

10 studies
  1. Tirzepatide is associated with major adverse cardiovascular events in humans (Type 2 diabetes; compared with metformin) (RR 0.339–0.433; HR 0.429–0.566; p<0.0001).

    “with larger reductions for tirzepatide vs metformin (RR 0.339-0.433, HR 0.429-0.566; p<0.0001; 385 vs 521 days)”

    HumansType 2 diabetes; compared with metformin2 years

    Diabetes drugs linked to fewer deaths in young adults

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide is associated with major adverse cardiovascular events in humans (elevated lipoprotein(a)) (HR 0.72; 95% CI, 0.58-0.89).

    “tirzepatide use was associated with a lower hazard of MACE (HR 0.72; 95% CI, 0.58-0.89)”

    Humanselevated lipoprotein(a)2 years

    Tirzepatide Use and Major Adverse Cardiovascular Events Among Patients with Elevated Lipoprotein(a)

    AHA Scientific Sessions 2026 abstract

  3. Tirzepatide is associated with major adverse cardiovascular events in humans (4.2% vs 7.4%; RR 0.56, 95% CI 0.38–0.83).

    “MACE (4.2% vs 7.4%; RR, 0.56; 95% CI, 0.38-0.83; p<0.05)”

    HumansPatients with obesity undergoing atrial fibrillation catheter ablation; at least 1 month of prior tirzepatide use90 days to 2 years post-ablationn = 1,772

    Tirzepatide Use and Cardiovascular Outcomes After Catheter Ablation for Atrial Fibrillation in Obese Patients

    AHA Scientific Sessions 2026 abstract

  4. Tirzepatide is associated with major adverse cardiovascular events in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide) (3-year HR 0.84, 95% CI 0.78–0.91; risk difference -1.09 per 1,000 patients).

    “Compared with semaglutide, tirzepatide was associated with lower rates of major adverse cardiovascular events”

    HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide3 years

    Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study

    Clinical Medicine Insights. Cardiology

  5. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with sitagliptin as a placebo proxy) (HR 0.68 (95% CI 0.58 to 0.80); risk difference -1.4% (95% CI -2.1% to -0.7%); NNT=70).

    “initiating tirzepatide reduced the risk of MACE compared with a placebo proxy among people with type 2 diabetes and established atherosclerotic cardiovascular disease”

    Humanscompared with sitagliptin as a placebo proxyup to one yearn = 52,971

    Tirzepatide is linked to lower risk of major heart events

    BMJ (Clinical research ed.)

  6. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (versus dulaglutide, 1-year follow-up) (HR 0.89 (95% CI 0.84–0.93) at 1 year).

    “MACE (HR: 0.89, 95% [CI: 0.84-0.93])”

    Humansversus dulaglutide, 1-year follow-up1 year

    Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis

    Clinical cardiology

  7. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (versus dulaglutide initiators) (HR 0.80, 95% CI 0.65-0.99).

    “Tirzepatide initiators experienced a lower rate of modified MACE versus dulaglutide initiators (IR 31.3 vs. 39.4, respectively; HR 0.80 [95% CI 0.65-0.99])”

    Humansversus dulaglutide initiators

    Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations

    Diabetes care

  8. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with SGLT2 inhibitors in adults with MASLD) (HR 0.68 (95% CI 0.58-0.80)).

    “TZP was also associated with lower risks of all-cause mortality (HR, 0.55; 95% CI, 0.43-0.71), MACEs (HR, 0.68; 95% CI, 0.58-0.80), and MALOs (HR, 0.66; 95% CI, 0.54-0.80).”

    Humanscompared with SGLT2 inhibitors in adults with MASLDn = 23,106

    Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study

    Hepatology international

  9. Tirzepatide is associated with major adverse cardiovascular events in humans (Type 2 diabetes without baseline dementia; versus SGLT2 inhibitors).

    “Tirzepatide and semaglutide reduced MACE vs SGLT2-i.”

    HumansType 2 diabetes without baseline dementia; versus SGLT2 inhibitors2 yearsn = 14,462

    Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study

    Diabetes research and clinical practice

  10. Tirzepatide lowers the risk of major adverse cardiovascular events in humans (class-level analysis versus placebo) (HR 0.79, 95% CI 0.69-0.91).

    “tirzepatide significantly reduced MACE (HR 0.79, 95% CI 0.69-0.91)”

    Reviewclass-level analysis versus placebo

    Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis

    Cardiovascular diabetology

Type 2 diabetes

downin humans3

3 studies
  1. Tirzepatide lowers the risk of type 2 diabetes in humans (stratified by glycemic high-risk criteria, compared with placebo) (90% to 99% reduction in high-risk groups; 68% to 91% in standard-risk groups).

    “Tirzepatide treatment was associated with a 90% to 99% reduction in new-onset T2D in the high-risk groups, vs 68% to 91% in the standard risk groups”

    Human trialstratified by glycemic high-risk criteria, compared with placebo3-year

    Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis

    Journal of the Endocrine Society

  2. Tirzepatide lowers the risk of type 2 diabetes in humans.

    “Tirzepatide treatment was associated with a significant reduction in incident T2D compared with placebo in 5 out of 6 glycemic risk subgroups shown in.”

    Human trial176 weeksn = 1,032

    Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis

    Journal of the Endocrine Society

  3. Tirzepatide lowers the risk of type 2 diabetes in humans (compared with semaglutide).

    “a lower incidence of new-onset type 2 diabetes”

    Reviewcompared with semaglutide

    Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review

    Cureus

  4. Tirzepatide lowers the risk of type 2 diabetes in the prediabetes subgroup of SURMOUNT-1.

    “Zepbound also reduced progression to type 2 diabetes mellitus (T2DM) through 176 weeks”

    Reviewin the prediabetes subgroup of SURMOUNT-1through 176 weeks

    Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation

    Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)

More on Type 2 diabetes

Heart failure

downin humans3HR 0.66–0.75

3 studies
  1. Tirzepatide lowers the risk of heart failure in women and men (HR 0.66 (95% CI 0.38, 1.18) for women, 0.61 (95% CI 0.33, 1.13) for men).

    “There was no heterogeneity in the effect of tirzepatide on the primary outcome of worsening HF or cardiovascular death by sex (HR 0.66 (95% CI 0.38, 1.18) for women, 0.61 (95% CI 0.33, 1.13) for men, treatment*sex interaction p=0.813; ).”

    Human trialin women and menn = 731

    Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial

    JACC. Heart failure

  2. Tirzepatide lowers the risk of heart failure in humans (obesity-related HFpEF) (HR: 0.66).

    “The effect of tirzepatide on the risk of worsening HF or cardiovascular death did not differ in women and men (HR: 0.66 and 0.61, respectively, interaction P = 0.81)”

    Human trialobesity-related HFpEF52 weeksfemalesn = 393

    Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial

    JACC. Heart failure

  3. Tirzepatide lowers the risk of heart failure in humans (compared with placebo, network meta-analysis) (OR 0.55 (95% CI 0.33-0.92)).

    “sotagliflozin (OR 0.50; 0.36-0.69; p-score=0.87), and tirzepatide (OR 0.55; 95% CI 0.33-0.92; p-score=0.80), had lowest odds of HF”

    Human trialcompared with placebo, network meta-analysis

    Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysis

    ADA Scientific Sessions 2026 abstract

  4. Tirzepatide lowers the risk of heart failure in humans (subgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists) (HR 0.75, 95% CI 0.58-0.97).

    “In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94) and heart failure (HR 0.75, 95% CI 0.58-0.97).”

    Reviewsubgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists

    Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis

    Diabetes, obesity & metabolism

More on Heart failure

Myocardial infarction

downin humans2upin humans1HR 0.67–1.26

3 studies
  1. Tirzepatide is associated with myocardial infarction in humans (5-year HR 1.26 (95% CI 1.12–1.42)).

    “MI risk was modestly elevated (5-year HR 1.26, 1.12-1.42, p=0.0002).”

    HumansNon-diabetic adults with obesity and established atherosclerotic cardiovascular disease; compared with semaglutide5 years

    Tirzepatide linked to more atrial fibrillation than semaglutide

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide is linked with a lower risk of myocardial infarction in humans.

    “tirzepatide demonstrated the largest observed association with reduced recurrent MI risk, followed by semaglutide.”

    Humans5-year

    Association of Glucagon-Like Peptide-1 Receptor Agonist Therapy with Risk of Recurrent Myocardial Infarction Following Acute Myocardial Infarction

    AHA Scientific Sessions 2026 abstract

  3. Tirzepatide is linked with a lower risk of myocardial infarction in humans (compared with sitagliptin as a placebo proxy) (HR 0.67 (95% CI 0.52 to 0.87); NNT=130).

    “tirzepatide was associated with a lower hazard for myocardial infarction (hazard ratio 0.67, 0.52 to 0.87; NNT=130)”

    Humanscompared with sitagliptin as a placebo proxyup to one yearn = 52,971

    Tirzepatide is linked to lower risk of major heart events

    BMJ (Clinical research ed.)

More on Myocardial infarction

Stroke

downin humans3RR 0.71

3 studies
  1. Tirzepatide is linked with a lower risk of stroke in humans (compared with other glp-1 receptor agonists) (absolute difference in stroke risk 2.1 percentage points at one year).

    “tirzepatide use was associated with lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and death from any cause”

    Humanscompared with other glp-1 receptor agonistsone year

    Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes

    Nature communications

  2. Tirzepatide lowers the risk of stroke in humans (Type 2 diabetes with established or high-risk cardiovascular disease; versus placebo) (RR 0.71; 95% CI 0.54–0.93).

    “Stroke was significantly reduced by tirzepatide (RR 0.71; 0.54-0.93)”

    ReviewType 2 diabetes with established or high-risk cardiovascular disease; versus placebo

    Comparative Cardiovascular Efficacy of GLP 1 Receptor Agonists in Type 2 Diabetes with Established or High-Risk Cardiovascular Disease A Network Meta Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

  3. Tirzepatide lowers the risk of stroke in humans (versus placebo, network meta-analysis).

    “Dulaglutide 1.5 mg and tirzepatide 15 mg significantly reduced stroke risk.”

    Reviewversus placebo, network meta-analysis15 mg

    Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis

    Diabetes, obesity & metabolism

More on Stroke

Atrial fibrillation

downin humans2upin humans1HR 0.41–1.04

3 studies
  1. Tirzepatide is associated with atrial fibrillation in humans (Patients with obesity without prior atrial fibrillation; compared with bariatric surgery) (HR 0.41, 95% CI 0.30–0.57; incidence 0.2% vs 0.6%; RD −0.4%).

    “Tirzepatide was associated with lower AF incidence compared with bariatric surgery (0.2% vs 0.6%; HR 0.41, 95% CI 0.30-0.57; RD –0.4%; p<0.001)”

    HumansPatients with obesity without prior atrial fibrillation; compared with bariatric surgery3 yearsn = 19,759

    Comparative Risk of Incident Atrial Fibrillation Following Bariatric Surgery, GLP-1 Receptor Agonists, and Tirzepatide in Patients with Obesity

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide is linked with a lower risk of atrial fibrillation in humans (versus subcutaneous semaglutide, 1:1 propensity-matched, at 12 and 18 months) (HR 0.83–0.84 at both horizons).

    “Significant reductions were also observed for incident AF (HR 0.83–0.84) and CKD progression (HR 0.82–0.84) at both horizons.”

    Humansversus subcutaneous semaglutide, 1:1 propensity-matched, at 12 and 18 monthsn = 54,978

    Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Study

    Research SquarePreprint

  3. Tirzepatide is linked with a higher risk of atrial fibrillation in humans (versus dulaglutide, 1-year follow-up) (HR 1.04 (95% CI 1.00–1.07) at 1 year).

    “Tirzepatide showed slightly higher 1-year atrial fibrillation risk (HR: 1.04, [1.00-1.07])”

    Humansversus dulaglutide, 1-year follow-up1 year

    Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis

    Clinical cardiology

More on Atrial fibrillation

Major adverse cardiovascular events

downin humans3HR 0.6–0.8

3 studies
  1. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (landmark target trial emulation, 90 days to 2 years post-transplant) (HR 0.60, 95% CI 0.45–0.80).

    “Kaplan–Meier cumulative incidence of MACE was 7.6% with tirzepatide versus 12.9% in controls”

    Humanslandmark target trial emulation, 90 days to 2 years post-transplant2 yearsn = 1,594

    Early tirzepatide after kidney transplantation in diabetes is associated with lower cardiovascular events and graft failure: a multinational target trial emulation

    ESC Congress 2026 abstract

  2. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (HR 0.80 (95% CI 0.69–0.92) at 12 months; HR 0.84 (95% CI 0.75–0.94) at 18 months).

    “Tirzepatide was associated with lower MACE at 12 months (hazard ratio [HR] 0.80; 95% CI 0.69–0.92)”

    Humansversus subcutaneous semaglutide, 1:1 propensity-matched, 12-month landmark; 18-month HR 0.84 (95% CI 0.75–0.94)n = 54,978

    Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Study

    Research SquarePreprint

  3. Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with semaglutide, propensity-matched TriNetX cohort, 1-year follow-up) (3.7% vs 4.1%; RR 0.918 (95% CI 0.862-0.978)).

    “Patients treated with tirzepatide experienced a significantly lower incidence of MACE”

    Humanscompared with semaglutide, propensity-matched TriNetX cohort, 1-year follow-up1 yearn = 47,804

    Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study

    Diabetes & vascular disease research

More on Major adverse cardiovascular events

HbA1c

downin humans3

3 studies
  1. Tirzepatide is associated with HbA1c in humans (Japanese adults with type 2 diabetes mellitus) (Median HbA1c change -1.0 percentage point (-11 mmol/mol)).

    “median HbA1c change was -1.0 percentage point (-11 mmol/mol)”

    HumansJapanese adults with type 2 diabetes mellitusmaximum observed dose ≤5 mg/week28 weeksn = 37

    Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  2. Tirzepatide is associated with HbA1c in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide).

    “Mean HbA1c was modestly lower with tirzepatide.”

    HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide

    Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study

    Clinical Medicine Insights. Cardiology

  3. Tirzepatide is associated with HbA1c in humans (Type 2 diabetes managed in secondary care) (HbA1c −17.7 mmol/mol; body weight −5.9 kg).

    “Mean HbA1c decreased by 17.7 mmol/mol and body weight by 5.9 kg (both p<0.001).”

    HumansType 2 diabetes managed in secondary careMean prescribed dose at follow-up: 5 mgMedian follow-up of 6.7 months51.9% femalesn = 295

    Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes

    TouchREVIEWS in endocrinology

More on HbA1c

Gastrointestinal adverse events

upin humans3+6.4% patients

3 studies
  1. Tirzepatide raises the risk of gastrointestinal adverse events in humans (compared with dulaglutide).

    “Gastrointestinal adverse events were common in both treatment groups but occurred more frequently with tirzepatide than dulaglutide.”

    Human trialcompared with dulaglutidemedian (IQR) treatment duration of 46.9 (34.6-50.6) monthsn = 13,165

    Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial

    JAMA cardiology

  2. Tirzepatide is associated with gastrointestinal adverse events in humans (real-world retrospective cohort) (6.4% of patients).

    “Gastrointestinal adverse events occurred in 6.4% of patients”

    Humansreal-world retrospective cohort52 weeksn = 203

    Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study

    Diabetes, obesity & metabolism

  3. Tirzepatide is associated with gastrointestinal adverse events in humans (most common adverse events, generally mild to moderate).

    “Gastrointestinal adverse events were the most common and were generally mild to moderate.”

    Review

    Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review

    Cureus

MACE-4

downin humans2HR 0.78–0.81

2 studies
  1. Tirzepatide lowers the risk of MACE-4 in humans (Type 2 diabetes and polyvascular cardiovascular disease; compared with dulaglutide) (HR 0.78 (95% CI 0.68–0.90), p<0.001).

    “Risk of MACE-4 and one of its components, coronary revascularization, were reduced on tirzepatide in the polyvascular group”

    Human trialType 2 diabetes and polyvascular cardiovascular disease; compared with dulaglutiden = 2,841

    Major Cardiovascular Adverse Events in People with Type 2 Diabetes and Polyvascular Disease: Tirzepatide versus Dulaglutide

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide lowers the risk of MACE-4 in humans (HR 0.81, 95% CI 0.69–0.95).

    “for MACE-4 0.81 (95%CI 0.69-0.95) and 0.91 (95%CI 0.83-1.00) in patients with and without HF, respectively.”

    Human trialType 2 diabetes, atherosclerotic cardiovascular disease and history of heart failure; compared with dulaglutide 1.5 mg weeklyup to 15 mg weeklyaverage 4 years

    Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis

    European journal of preventive cardiology

Ischemic colitis

upin humans2

2 studies
  1. Tirzepatide is associated with ischemic colitis in a patient with type 2 diabetes, severe obesity, and cardiovascular comorbidities.

    “This case highlights a potential association between tirzepatide therapy and ischemic colitis.”

    Human trialin a patient with type 2 diabetes, severe obesity, and cardiovascular comorbiditiessecond dosefemales

    Acute ischaemic colitis after initiation of tirzepatide in an elderly patient with type 2 diabetes

    Emergency Care Journal

  2. Tirzepatide is associated with ischemic colitis in humans (Preexisting ischemic colitis and multiple comorbidities).

    “This case raises concern for a potential association between tirzepatide use and ischemic colitis in a patient with preexisting risk factors.”

    HumansPreexisting ischemic colitis and multiple comorbiditiesinjectionfemales

    Ischemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse Effect

    Cureus

More on Ischemic colitis

Concordance of predicted microbial functional effects

upin humans1

1 study
  1. Tirzepatide is associated with concordance of predicted microbial functional effects in humans (comparison of tirzepatide and semaglutide in Type 2 diabetes) (Pearson r = 0.450; 67.1% concordant direction across 2106 predicted EC features; p < 0.001).

    “Across 2106 predicted EC features, longitudinal effects were positively correlated between tirzepatide and semaglutide (67.1% concordant direction; Pearson r = 0.450, p < 0.001).”

    Human trialcomparison of tirzepatide and semaglutide in Type 2 diabetes16 weeks

    Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the <scp>OMDOT</scp> ‐1 Randomized Controlled Trial

    Diabetes, obesity & metabolism

Gut microbial genus trajectories

mixedin humans1

1 study
  1. Tirzepatide is associated with gut microbial genus trajectories in humans (Type 2 diabetes; versus conventional treatment) (q < 0.05).

    “Longitudinal trajectories relative to the control group differed for several genera, including Romboutsia_B , Barnesiella and Ruminococcus_E with both treatments and Vescimonas with tirzepatide”

    Human trialType 2 diabetes; versus conventional treatment16 weeks

    Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the <scp>OMDOT</scp> ‐1 Randomized Controlled Trial

    Diabetes, obesity & metabolism

More on Gut microbial genus trajectories

All 196

Has tirzepatide been tested in people?

73 of 181 about aging

Yes: 226 trials and 480 observational studies in people have been published, and 167 trials are registered.

Approved

Repurposing

40 of 56

Every condition in trials

  • Fasting

    Phase 4Completed1 trial

  • Motor Activity

    Phase 3Results posted2 trials

  • Addictive Behavior

    Phase 2Recruiting2 trials

  • Prostatic neoplasm

    Phase 2Recruiting2 trials

  • Autosomal dominant polycystic kidney

    Phase 2Recruiting1 trial

  • Biological aging

    Phase 2Enrolling by invitation1 trial

All 10

Who is developing tirzepatide?

3 companies: Eli Lilly, Hudson Biotech and Novo Nordisk.

Companies
  • Eli LillyPhase 4type 2 diabetes, psoriasis
  • Hudson BiotechPhase 3obesity, overweight without type 2 diabetes with weight related comorbidities
  • Novo NordiskPhase 3type 2 diabetes, overweight

Trial sponsors

Funding

11 grants since 2023

National Institute of Diabetes and Digestive and Kidney Diseases$2.2MNational Institute on Alcohol Abuse and Alcoholism$396KNational Institute for Health Research£1M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Tirzepatide reduces cardiovascular and kidney events versus dulaglutide in a human trial; independent labs reproduce human weight and HbA1c reductions and mouse oxidative stress reductions, though some weight and HbA1c results differ. Eli Lilly funds work, sponsors trials and has author ties. Aging-related trials are registered; some trials across uses ended over a year ago without posted results.

  2. Summary rewritten as its findings changed.

    As it read before

    Tirzepatide reduces cardiovascular and kidney outcomes versus dulaglutide in a human trial; independent labs reproduce human weight and HbA1c reductions, but some results show weight gain or no clear weight or HbA1c effect. There are 67 registered aging trials; four trials overall ended over a year ago without posted results. Developer Eli Lilly and Company funds papers and sponsors trials.

  3. Summary rewritten as its findings changed.

    As it read before

    Human studies associate tirzepatide with lower mortality in type 2 diabetes with established atherosclerotic cardiovascular disease; independent labs reproduce weight and HbA1c reductions, but some studies report no change. Registrations include 42 aging-related trials; five trials across uses ended over a year ago without posted results or linked papers. Developer Eli Lilly funds work and sponsors trials, and authors declare ties to it.

  4. Summary rewritten as its findings changed.

    As it read before

    A human trial reports lower combined cardiovascular and kidney risk with tirzepatide in type 2 diabetes with cardiovascular disease. Independent labs reproduce human HbA1c and weight reductions, but a human study reports no weight change. Of registered trials, 21 concern aging; five ended over a year ago without posted results or citing papers; developer Eli Lilly funds papers and sponsors trials.

Latest

Dec 2025: 49Jan 2026: 73Feb 2026: 60Mar 2026: 95Apr 2026: 10May 2026: 13Jun 2026: 59Jul 2026: 39Aug 2026: 86Sep 2026: 82Oct 2026: 132Nov 2026: 114812 papers in 12 months

See all 1,798 papers on tirzepatide